Stockholm, Sweden – January 8, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, today announced that it will commence a tender offer through its wholly owned, direct subsidiary Matador Subsidiary, Inc., a Delaware corporation (“Purchaser”), to purchase all outstanding shares of common stock of Marinus Pharmaceuticals, …
